Form 4: Evolent Health Director Acquires Stock

Brendan B. Springstubb, a Director at Evolent Health, Inc., acquired 41,096 shares of Class A Common Stock through a restricted stock unit grant.

Summary

• Brendan B. Springstubb, a Director of Evolent Health, Inc., was granted 41,096 restricted stock units (RSUs) on June 4, 2026.
• These RSUs are part of the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The securities vest on the earlier of June 4, 2027, or the date of the Company's 2027 annual meeting, contingent upon continued service.
• Following this transaction, Mr. Springstubb beneficially owns 99,917 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard equity grant to a director rather than a purchase or sale of shares on the open market.

Positives

• Director acquisition of stock can signal confidence in the company's future prospects.
• The grant of RSUs aligns management's interests with long-term shareholder value.

Risks

• Vesting is contingent on continued service, meaning the shares are not fully owned until the vesting date.
• The value of the acquired shares is subject to market fluctuations until vesting and potential sale.

Future Outlook

The vesting of the restricted stock units is scheduled for June 4, 2027, or the date of the Company's 2027 annual meeting, subject to continued service.

Industry Context

StockSavvy.ai notes that insider grants of equity, such as these restricted stock units, are common within the healthcare technology sector as a method to attract and retain key leadership talent and align their compensation with company performance.

Stakeholder Impact

• Shareholders: The grant of RSUs is a form of compensation that dilutes existing ownership slightly but aims to incentivize long-term performance.
• Employees: The compensation plan under which these RSUs were granted is a standard practice for attracting and retaining executive talent.

Next Steps

• Continued service by Mr. Springstubb until the vesting date.
• Vesting of 41,096 restricted stock units on or before June 4, 2027.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Securities Ownership